Novaliq GmbH strengthens Executive Management team by appointing Oliver Schlüter, PhD as Managing Director and CFO, and Hartmut Voss, PhD as CBO

Novaliq GmbH, a clinical stage specialty pharmaceutical company with a disruptive drug delivery technology platform transforming poorly soluble drugs into effective therapeutics for ophthalmology, announced today that Oliver Schlüter, PhD, has joined the company as Managing Director and Chief Financial Officer (CFO), and that Hartmut Voss, PhD, has been named Chief Business Officer (CBO). Previously,…